Hydroxychloroquine study withdrawn over data concerns
The anti-malaria drug has been touted as a “miracle cure” for Covid-19, but the scientific evidence so far is confusing.
Associated Press
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
This content was published on
2 minutes
swissinfo.ch/jc
The article, published in the Lancet medical journal on May 22, was by Harvard Medical School, the University of Utah and Switzerland’s University Hospital Zurich. It found that antimalarial drugs hydroxychloroquine and a similar drug chloroquine showed no benefit against Covid-19 and could even increase the risk of heart arrhythmia and death.
But three of the four authors, including Frank Ruschitzka of the University Hospital of Zurich, have now retracted it.
On Thursday, they said that Surgisphere, the company that provided the data, would not transfer the dataset for an independent review and that they “can no longer vouch for the veracity of the primary data sources”. The fourth author of the study, Sapan Desai who is chief executive of Surgisphere, declined to comment on the retraction, according to Reuters.
In a June 5 update to its original press release, Zurich University Hospital department of cardiology said it was “only called in by Harvard Medical School to co-author the paper during the evaluation phase” and “was not involved in the provision of the data by the company Surgisphere or in the evaluation of the data collection”. “Prof. Ruschitzka had no contact with the company,” it adds. “After reservations became known, the authors immediately requested an external audit.”
Controversy
The antimalarial drug has been surrounded by controversy. Claimed by French professor Didier Raoult to be a miracle cure for the new coronavirus, it has also been touted by US President Donald Trump and Brazilian President Jair Bolsonaro. The Lancet article caused the suspension of several studies into its use for Covid-19.
At the height of the pandemic in March, Swiss hospitals all had their own policies with regard to administration of the drug, according to data gathered by Swiss television RTS. In mid-May most of the big hospitals harmonised their practise, deciding to stop using chloroquine to treat Covid-19 except for patients taking part in clinical trials.
The World Health Organization paused hydroxychloroquine trials after The Lancet study was released but said on Wednesday it was ready to resume trials.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
Higher direct payments fail to curb scrub encroachment on alpine pastures
This content was published on
The scrub encroachment on Swiss alpine pastures leads to the loss of grassland and damages the typical landscape. It is also responsible for the decline in biodiversity. Despite higher direct payments, the bushes continue to spread.
Head of Swiss financial regulator’s Banks division quits
This content was published on
Thomas Hirschi, head of the Banks division of the Swiss Financial Market Supervisory Authority FINMA will leave at the end of August.
Swiss population satisfied with life according to survey
This content was published on
In a survey, the population of German-speaking and French-speaking Switzerland expressed general satisfaction with their lives. Respondents were less happy with politics and their personal finances, according to the online comparison service Moneyland.
WHO ‘extremely concerned’ about growing vaccination scepticism
This content was published on
According to the World Health Organisation (WHO), vaccination scepticism and a collapse in funding for vaccination campaigns pose a major threat to the health of the world's population.
High-net-worth individuals prioritise well-being over material possessions
This content was published on
The priorities of wealthy private individuals have shifted against the backdrop of ongoing geopolitical tensions and trade disputes. While spending on luxury goods is declining, demand for travel and experiences is unabated.
Swiss researchers sequence genome of 1918 Spanish flu virus
This content was published on
Researchers from the Universities of Basel and Zurich (UZH) have sequenced the genome of the Spanish flu virus, thanks to a sample taken from an 18-year-old Swiss boy who died in the city on the Limmat in 1918, when the pandemic spread around the world.
Swiss martyr beatified in Barcelona by Catholic Church
This content was published on
François-Benjamin May (1870-1909), a member of the Marist Brothers congregation, has been recognised as a 'blessed' by the Catholic Church.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Study finds hydroxychloroquine linked to higher death rate in Covid-19 patients
This content was published on
An international research team led by the University Hospital of Zurich and Harvard Medical School finds controversial antimalarial drugs show no benefit against Covid-19.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.